Heather Daley
YOU?
Author Swipe
View article: In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant
In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant Open
Introduction/Background: Minimal residual disease (MRD) negative complete response portends better prognosis in multiple myeloma (MM) pts. Autologous stem cell transplant (ASCT) is a well-established consolidation approach. BHV-1100, an An…
View article: Supplementary Data S3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S3: Condensation of Oligonucleotide Process.
View article: Supplementary Data S2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S2: GM-CSF Microsphere Preparation Using a Double Emulsion Process. The diagram illustrates the step-by-step method for encapsulating GM-CSF within PLGA microspheres.
View article: Supplementary Data S5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S5. Aggregate cell densities are shown for five patients with pre-and post-treatment biopsies assayed by multiplex immunofluorescence (mIF) for markers of CD4+, CD8+, CD68+, CD11c and SOX10+ PD-L1+ cells (accompanying …
View article: Supplementary Table 2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 2. Adverse Events (possibly related to vaccine)
View article: Supplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 1. CyTOF panel profiles innate and adaptive immune populations in PBMCs.
View article: Supplementary Table 3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 3. Adverse Events (all attributions)
View article: Supplementary Table 7 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 7 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 7. Erythema and Induration by Vaccine Administration and Cohort
View article: Supplementary Table 5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 5. Erythema and Induration by Vaccine Administration and Cohort
View article: Supplementary Table 4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 4. Best Overall Response (BOR)
View article: Supplementary Data S6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S6. The Z-score normalized expression of markers from the CyTOF panel are shown for the clusters labeled “CD163+ Monoctyes”, “NK Cells”, and “CD4 T Cells”. Markers on the Y-axis are ordered from most to least enriched.
View article: Supplementary Data S1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S1: Patient Flow Diagram
View article: Supplementary Table 6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 6. Best Overall Response (BOR)
View article: Supplementary Data S4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S4. Vaccine characterization. A-F. Plots showing the distributions of the indicated vaccine parameters for each vaccinated patient (labelled 1 through 23). Scaffold moduli and toughness were only measured beginning at …
View article: Supplementary Table 6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 6. Best Overall Response (BOR)
View article: Supplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 1. CyTOF panel profiles innate and adaptive immune populations in PBMCs.
View article: Supplementary Table 3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 3. Adverse Events (all attributions)
View article: Supplementary Data S5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S5. Aggregate cell densities are shown for five patients with pre-and post-treatment biopsies assayed by multiplex immunofluorescence (mIF) for markers of CD4+, CD8+, CD68+, CD11c and SOX10+ PD-L1+ cells (accompanying …
View article: Supplementary Data S1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S1: Patient Flow Diagram
View article: Data from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Data from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
The optimal means to prime for effective antitumor immunity in a patient with cancer remain elusive in the current era of checkpoint blockade. Crafting a strategy to amplify the number and function of CD8+ T cells while blocking regulatory…
View article: Supplementary Data S4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S4. Vaccine characterization. A-F. Plots showing the distributions of the indicated vaccine parameters for each vaccinated patient (labelled 1 through 23). Scaffold moduli and toughness were only measured beginning at …
View article: Supplementary Data S6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S6. The Z-score normalized expression of markers from the CyTOF panel are shown for the clusters labeled “CD163+ Monoctyes”, “NK Cells”, and “CD4 T Cells”. Markers on the Y-axis are ordered from most to least enriched.
View article: Supplementary Table 5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 5. Erythema and Induration by Vaccine Administration and Cohort
View article: Supplementary Table 7 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 7 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 7. Erythema and Induration by Vaccine Administration and Cohort
View article: Supplementary Table 4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 4. Best Overall Response (BOR)
View article: Supplementary Data S3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S3: Condensation of Oligonucleotide Process.
View article: Supplementary Table 2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Table 2. Adverse Events (possibly related to vaccine)
View article: Supplementary Data S2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Data S2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma Open
Supplementary Figure S2: GM-CSF Microsphere Preparation Using a Double Emulsion Process. The diagram illustrates the step-by-step method for encapsulating GM-CSF within PLGA microspheres.
View article: Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes
Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes Open
In this phase 1/2 trial, AVT001 did not result in dose-limiting adverse events. Potential signals of efficacy observed here warrant further evaluation in a fully powered trial. (Funded by Avotres Inc. and the Division of Diabetes, Endocrin…